A novel brain targeted 5-FU derivative with potential antitumor efficiency and decreased acute toxicity: Synthesis, in vitro and in vivo evaluation

Pharmazie

Volumn 69, Issue 4, 2014, Pages 271-276

  Chen, Hui ^a   Wu, Wenqi ^a   Li, Yanping ^a   Gong, Tao ^a   Sun, Xun ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; N,N DIMETHYLETHYLENEDIAMINE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CANCER CELL CULTURE; CHEMICAL BOND; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PH; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALGORITHMS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BRAIN; BUFFERS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FLUOROURACIL; HYDROGEN-ION CONCENTRATION; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; RATS; RATS, WISTAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

EID: 84898847844     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3200     Document Type: Article

References (32)

1. Brem H, Lawson HC (1999) The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer 86: 197-199. (Pubitemid 29327575)
2. Chen Y, Dalwadi G, Benson H (2004) Drug delivery across the blood-brain barrier. Current Drug Deliv 1: 361-376.
3. Cheng Y, Zak O, Aisen P, Harrison S C, Walz T (2004) Structure of the human transferrin receptor-transferrin complex. Cell 116: 565-576. (Pubitemid 38264433)
4. Chung SM, Yoon EJ, Kim SH, Lee MG, Heejoo L, Park MK, Chong-Kook K (1991) Pharmacokinetics of 5-fluorouracil after intravenous infusion of 5-fluorouracil-acetic acid-human serum albumin conjugates to rabbits. Int J Pharm 68: 61-68.
5. Daher G C, Harris B E, Diasio R B (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48: 189-222.
6. Daishu Z, Tao J, Huashi G, Xin Q, Quan T, Fulong L (2001) Synthesis of aminoglucose conjugates of 5-fluorouracil-1-acetic acid and 5-fluorouracil-1- propanoic acid and their antitumor activities. J Chin Pharm Sci 10: 193-195.
7. Daumar P, Decombat C, Chezal J-M, Debiton E, Madesclaire M, Coudert P, Galmier M-J (2011) Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. Eur J Med Chem 46: 2867-2879.
8. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte P (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropy rimidine dehydrogenase activity in cancer patients. Ann Oncol 12: 1301-1306. (Pubitemid 32994761)
9. Fournier E, Passirani C, Colin N, Breton P, Sagodira S, Benoit J-P (2004) Development of novel 5-FU-loaded poly (methylidene malonate 2.1. 2)-based microspheres for the treatment of brain cancers. Eur J Pharm Biopharm 57: 189-197. (Pubitemid 38283694)
10. Fournier E, Passirani C, Vonarbourg A, Lemaire L, Colin N, Sagodira S, Menei P, Benoit J-P (2003) Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1. 2-based microspheres on C6 glioma. Int J Pharm 268: 31-35. (Pubitemid 37487820)
11. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, Thun M (2007) Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society 1.
12. Grem J L (1996) 5-Fluoropyrimidines. Cancer chemotherapy and biotherapy: principles and practice:pp. 149-212.
13. Gududuru V, Hurh E, Dalton JT, Miller DD (2004) Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett 14: 5289-5293. (Pubitemid 39348915)
14. Heggie G D, Sommadossi J-P, Cross D S, Huster W J, Diasio R B (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206. (Pubitemid 17074634)
15. Heidelberger C, Chaudhuri N, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer R, Pleven E, Scheiner J (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179: 663-666.
16. Huang J, Wang JW, Gong T, Zhang ZR (2007) Synthesis and characterization of insulin-5-FU conjugate, enabling insulin as multi-drug carrier via dendritic approach. Chin Chem Lett 18: 247-250.
17. Kang N I, Lee S M, Maeda M, Ha C S, Cho W J (2002) Synthesis, antitumour and DNA replication activities of polymers containing vinyl-(5-fluorouracil)- ethanoate. Polym Int 51: 443-449. (Pubitemid 34490291)
18. Malakoutikhah M, Teixidó M, Giralt E (2011) Shuttle-mediated drug delivery to the brain. Angew Chem Int Ed 50: 7998-8014.
19. Ohya Y, Takei T, Kobayashi H, Ouchi T (1993) Release behaviour of 5-fluorouracil from chitosan-gel microspheres immobilizing 5-fluorouracil derivative coated with polysaccharides and their cell specific recognition. J Microencapsul 10: 1-9. (Pubitemid 23069809)
20. Ouchi T, Tada M, Matsumoto M, Ohya Y, Hasegawa K, Arai Y, Kadowaki K, Akao S, Matsumoto T, Suzuki S (1998) Design of macromolecular prodrug of 5-fluorouracil using N-acetylpolygalactosamine as a targeting carrier to hepatoma. React Funct Polym 37: 235-244. (Pubitemid 128400570)
21. Ouyang L, He D, Zhang J, He G, Jiang B, Wang Q, Chen Z, Pan J, Li Y, Guo L (2011) Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation. Bioorgan Med Chem 19: 3750-3756.
22. Pang Z, Feng L, Hua R, Chen J, Gao H, Pan S, Jiang X, Zhang P (2010) Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 7: 1995-2005.
23. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2: 3-14.
24. Qian ZM, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54: 561-587. (Pubitemid 35351196)
25. Scherf U, Ross DT, Waltham M, Smith L H, Lee J K, Tanabe L, Kohn K W, Reinhold W C, Myers TG, Andrews DT (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244. (Pubitemid 30132190)
26. Soni S, Babbar A K, Sharma R K, Maitra A (2006) Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J Drug Target 14: 87-95.
27. Soni V, Kohli D, Jain S (2005) Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target 13: 245-250. (Pubitemid 41086289)
28. Van Kuilenburg A (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939.
29. Yang Z, Wang L, Yang X, Wang D, Li Y (2000) Pharmacological study on antitumor activity of 5-fluorouracil-1-acetic acid and its rare earth complexes. J Rare Earth 18.(2).
30. Zhang Q, Liang Z, Chen L, Sun X, Gong T, Zhang Z (2012a) Novel brain targeting prodrugs of naproxen based on dimethylamino group with various linkages. Arzneim.-Forsch 62: 261-266.
31. Zhang X, Liu X, Gong T, Sun X, Zhang Z-R (2012b) In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery. Acta Pharmacol Sin 33: 279-288.
32. Zuo D S, Jiang T, Guan H S, Qi X,Wang K Q, Shi Z (2001) Synthesis, structure and antitumor activity of dibutyltin oxide complex with 5-fluorouracil derivatives. Chin J Chem 19: 1141-1145. (Pubitemid 33749731)